Tuesday, February 19, 2019

FDA Approval

New FDA approval: EyeBOX.

What is it? The first noninvasive test to help diagnose a concussion. How does it work? The patient watches a four minute video while the software analyzes...

FDA Approvals in 2018 Recap!

We had 13 eye-related FDA approvals in 2018. Here is your quick rundown. 1. Dexycu - It's a sustained-release...

Persistence pays off.

The FDA has (finally) approved Dextenza. What is Dextenza? It's a dexamethasone insert, placed through the punctum into the canaliculus and delivers dexamethasone to the ocular surface...

A new FDA approval: Yutiq.

What is it? It's a fluocinolone acetonide intravitreal implant. Who is it for? It's approved for patients with chronic noninfectious posterior uveitis. Tell me more about the implant. It uses...

Sun Pharma is cranking out the FDA approvals.

Let's talk about Xelpros, the latest FDA approved drop out of Sun Pharma. What is it? Latanoprost 0.005%. The FDA approval is for the treatment of ocular...

New FDA approval: Inveltys.

Inveltys is approved for the treatment of postoperative inflammation and pain following ocular surgery. What is it? It's a steroid drop, loteprednol etabonate ophthalmic suspension 1% to be...

New FDA approval: OXERVATE.

Oxervate was approved on August 22nd for the treatment of neurotrophic keratitis. Refresh me on neurotrophic keratitis. Patients with neurotrophic keratitis have decreased corneal sensitivity, epithelial breakdown,...

And then there were three.

We've got a new dry eye med to prescribe. The FDA just approved Cequa ("see-qwa"), a prescription eye drop indicated to increase tear production in patients...

Roclatan may be on your sample shelf soon.

What is Roclatan? It's a drop used once daily to lower IOP and it's a combo of two drugs, latanoprost and Rhopressa. You've heard a lot...

Third time’s a charm.

Ocular Therapeutix resubmits Dextenza to the FDA (for the third time). What is Dextenza? It's a dexamethasone insert, placed through the punctum into the canaliculus and is designed to...

Want this news in your inbox?

Subscribe to the weekly email (it’s free!)